Tenaya Therapeutics’ (TNYA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research report released on Monday,Benzinga reports. HC Wainwright currently has a $18.00 price target on the stock.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity Group restated a “buy” rating and set a $16.00 price target on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Chardan Capital lowered their price target on Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $14.75.

Tenaya Therapeutics Stock Performance

NASDAQ:TNYA opened at $2.96 on Monday. The firm has a market capitalization of $234.49 million, a price-to-earnings ratio of -2.06 and a beta of 2.34. Tenaya Therapeutics has a 52-week low of $1.61 and a 52-week high of $7.01. The stock has a fifty day moving average of $2.04 and a 200 day moving average of $2.85.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.07. Equities analysts forecast that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TNYA. abrdn plc purchased a new position in Tenaya Therapeutics during the 3rd quarter valued at about $1,063,000. Vanguard Group Inc. increased its holdings in Tenaya Therapeutics by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock valued at $14,973,000 after purchasing an additional 403,472 shares during the period. American Century Companies Inc. increased its holdings in Tenaya Therapeutics by 27.7% during the 2nd quarter. American Century Companies Inc. now owns 102,114 shares of the company’s stock valued at $317,000 after purchasing an additional 22,146 shares during the period. Dimensional Fund Advisors LP increased its holdings in Tenaya Therapeutics by 42.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company’s stock valued at $316,000 after purchasing an additional 30,446 shares during the period. Finally, Algert Global LLC purchased a new position in Tenaya Therapeutics during the 2nd quarter valued at about $74,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.